<SEC-DOCUMENT>0001493152-25-009108.txt : 20250304
<SEC-HEADER>0001493152-25-009108.hdr.sgml : 20250304
<ACCEPTANCE-DATETIME>20250304215802
ACCESSION NUMBER:		0001493152-25-009108
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250304
DATE AS OF CHANGE:		20250304

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scinai Immunotherapeutics Ltd.
		CENTRAL INDEX KEY:			0001611747
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89384
		FILM NUMBER:		25708569

	BUSINESS ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000
		BUSINESS PHONE:		972-8-9302529

	MAIL ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BiondVax Pharmaceuticals Ltd.
		DATE OF NAME CHANGE:	20140624

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LCK JNK 1 LLC
		CENTRAL INDEX KEY:			0002055074
		ORGANIZATION NAME:           	
		IRS NUMBER:				332550030
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		3105 NW 107TH AVENUE
		STREET 2:		SUITE 103
		CITY:			DORAL
		STATE:			FL
		ZIP:			33172
		BUSINESS PHONE:		617-304-1099

	MAIL ADDRESS:	
		STREET 1:		3105 NW 107TH AVENUE
		STREET 2:		SUITE 103
		CITY:			DORAL
		STATE:			FL
		ZIP:			33172
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001493152-25-007954</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: LCK JNK 1 LLC -->
          <cik>0002055074</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>American Depository Shares, each representing 4,000 Ordinary Shares, no par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>02/09/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001611747</issuerCik>
        <issuerName>Scinai Immunotherapeutics Ltd.</issuerName>
        <issuerCusip>09073Q203</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>JERUSALEM BIOPARK, 2ND FLOOR</com:street1>
          <com:street2>Hadassah Ein Kerem Campus</com:street2>
          <com:city>Jerusalem</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>0000000</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>LCK JNK 1 LLC</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>80757.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>80757.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>80757.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.5</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>Based on 3,411,983,584 ordinary shares outstanding as of September 30, 2024, as disclosed by the issuer on November 22, 2024. Does not include pre-funded warrants exercisable for an additional 80,757 American Depositary Shares ("ADSs") distributable to Richard J. Kertzman, or an entity held by Mr. Kertzman or an affiliate, which ADSs may not be exercised if such exercise would result in beneficial ownership in excess of 9.99% of the ordinary shares outstanding of Scinai Immunotherapeutics Ltd. Future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Scinai Immunotherapeutics Ltd.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, 0000000</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>LCK JNK 1 LLC

The shares reported herein are directly held by LCK JNK 1 LLC. Richard J. Kertzman is the managing member of LCK JNK LLC. Accordingly, Mr. Kertzman may be deemed to indirectly beneficially own the securities of the Issuer held by LCK JNK LLC.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>3105 NW 107th Avenue, Suite 103, Doral, FL 33172</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>80,757</amountBeneficiallyOwned>
        <classPercent>9.5%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>80,757</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>80,757</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>LCK JNK 1 LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Richard J. Kertzman</signature>
        <title>Richard J. Kertzman, Sole Member</title>
        <date>03/04/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
